WHO recommendations for influenza virus vaccine composition for the 2018 southern hemisphere influenza season
The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.
Understanding the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines
This meeting was designed to offer a place to exchange the latest information on into the development of narcolepsy following vaccination with one of the 2009 adjuvanted influenza A(H1N1) vaccines.
Update on narcolepsy cases associated with Pandemrix vaccination in 2009 in the Netherlands
In November 2014, the Pharmacovigilance Centre of Netherlands (Lareb) provided an updated overview of Dutch cases of narcolepsy reported to have a link to Pandemrix.
No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix™ Vaccination Campaign in Finland
This is the first published study where an attempt has been made to understand the possible biological mechanisms behind development of narcolepsy following vaccination with Pandemrix™.
New Swedish Registry study confirms increased risk of narcolepsy in children and adolescents after vaccination with Pandemrix
This observational cohort study utilizing electronic health care records covering 5.8 million Swedes confirmed an increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents (<
Association of receipt of Pandemrix™ and narcolepsy in children and adolescents in the UK (England)
This is the sixth EU Member State reporting an association between the development of narcolepsy and vaccination with the AS03-adjuvanted influenza A H1N1 (2009) pandemic vaccine Pandemrix.
How effective were neuraminidase inhibitors during the 2009 pandemic?
This systematic review and meta-analysis of observational data from an established group of specialists assessed treatment outcomes for all three neuraminidase inhibitors (NAIs); oseltamivir, zanamivir and peramivir given to hospitalised patients with influenza A(H1N1)pdm09 during the 2009 pandemic.
Narcolepsy and Pandemrix Vaccine – an association in adults as well as children
In September 2010 Sweden and Finland noted a number of children had developed narcolepsy seemingly in association with having received the pandemic vaccine used almost exclusively in those countries (Pandemrix)
New ECDC technical report on “Narcolepsy in association with pandemic influenza vaccination – a multi-country European epidemiological investigation”
Results from Vaccine Adverse Event Surveillance and Communication (VAESCO) Consortium studies confirm an association between vaccination with Pandemrix® and an increased risk of narcolepsy in children and adolescents (5 to 19 years of age) in Sweden and Finland.
Oseltamivir-resistant influenza A(H1N1)pdm09 influenza virus in Dutch travellers returning from Spain, August 2012
Antiviral susceptibility is a key area for influenza surveillance as it can affect patient management, prevention of outbreaks and pandemic preparedness.